Viewpoints

A single, global tooling standard would offer many benefits, but one has been slow to emerge.

Social media tools have taken over many aspects of our lives, now including regulatory info.

Just when things seem to be looking up, the unexpected problem occurs.

INTERPHEX 2011 aims to address the industry's unique characteristics.

The recent India–EU summit was expected to bring news about the upcoming Free Trade Agreement between the EU and India; however, a dispute regarding the supply of generic drugs from India to developing countries has taken centre stage.

Follow-ons were all the rage at this year's JP Morgan Healthcare Conference.

Government and private sector efforts take on counterfeit drugs online.

Legislation has hampered cross-border drug importation and limited choice.

Taking care to note, file and re-check information can save one from future mishaps.

Direct-to-consumer (DTC) advertising is firmly entrenched in the US, but has historically been considered as an inappropriate means of communication in Europe for prescription-only medicines.

Capable of great works, pharma as a whole still yields to the lesser angels of its nature.

Supportive public policy is needed in order for innovation to flourish.

World AIDS Day 2010 reminds us that prevention and hope can help fight the disease.

Sometimes doing what you think is right ends up being completely and utterly wrong.

So 2010 is nearly over and what a year it's been for our industry.

As technology advances, industry's needs are growing.

Scientists and practitioners must work together for the overall good of the patient.

Remaining calm, cool, and collected during mergers and inspections is a feat in itself.

Connecting science and policy might increase support for innovation.

There has been increasing cooperation between the EMA and the FDA in recent years, and this looks set to continue in the future.

The reopened debate over embryonic-stem-cell research could stifle many other scientific pursuits.

From disagreement to denial, being cordial about quality control can be challenging.

In light of compendial changes, representatives of the US Pharmacopeia and an industry consortium provide perspectives on cap and ferrule labels.

Every day we are exposed to messages of advice and guidance on what we can do to reduce the damaging effects that our lifestyles have on the environment.

The early part of the decade saw a decline in vaccine sales and manufacture, but finally the industry is bouncing back, with Europe particularly well placed to make an impact.

Industry efforts toward global healthcare surpass average expectations.

Pending legislation may give FTC the authority to regulate all Hatch-Waxman settlements.

From weekend deliveries to nonsterile gloves, a single exception can make a product fall flat.

New data provide insight into pharma-industry professionals' daily lives.

No one can deny the power of social media; it has revolutionised communication and empowered consumers, creating a medium that allows the free flow of information with no authority to control it.